Cancer Biologic Therapy Market

ID: MRFR/Pharma/0123-CR 128 Pages Rahul Gotadki Last Updated: November 16, 2026
Cancer Biological Therapy Market Research Report By Type of Therapy (Monoclonal Antibodies, Vaccines, Cytokines, Gene Therapy), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer), By Administration Route (Intravenous, Subcutaneous, Oral, Intramuscular), By End User (Hospitals, Cancer Research Institutes, Pharmaceutical Companies) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) Forecast to 2035
Cancer Biologic Therapy Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.45%
2024 Market Size$ 115.13 Billion
2025 Market Size$ 121.4 Billion
2035 Market Size$ 206.4 Billion
Key Players
Roche
Bristol-Myers Squibb
Amgen
Merck & Co.
Novartis
Gilead Sciences
Opportunities
  • Rising Incidence of Cancer
  • Advancements in Biotechnology
  • Increased Investment in Cancer Research
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Monoclonal Antibodies | |
      2. 4.1.2 Vaccines | |
      3. 4.1.3 Cytokines | |
      4. 4.1.4 Gene Therapy |
    2. 4.2 Healthcare, BY Cancer Type (USD Billion) | |
      1. 4.2.1 Breast Cancer | |
      2. 4.2.2 Lung Cancer | |
      3. 4.2.3 Colorectal Cancer | |
      4. 4.2.4 Prostate Cancer |
    3. 4.3 Healthcare, BY Administration Route (USD Billion) | |
      1. 4.3.1 Intravenous | |
      2. 4.3.2 Subcutaneous | |
      3. 4.3.3 Oral | |
      4. 4.3.4 Intramuscular |
    4. 4.4 Healthcare, BY End User (USD Billion) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Cancer Research Institutes | |
      3. 4.4.3 Pharmaceutical Companies |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Roche (CH) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Bristol-Myers Squibb (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Amgen (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Merck & Co. (US) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Novartis (CH) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Gilead Sciences (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 AstraZeneca (GB) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Pfizer (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Johnson & Johnson (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY CANCER TYPE |
    8. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    9. 6.6 US MARKET ANALYSIS BY END USER |
    10. 6.7 CANADA MARKET ANALYSIS BY TYPE |
    11. 6.8 CANADA MARKET ANALYSIS BY CANCER TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    13. 6.10 CANADA MARKET ANALYSIS BY END USER |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY TYPE |
    16. 6.13 GERMANY MARKET ANALYSIS BY CANCER TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    18. 6.15 GERMANY MARKET ANALYSIS BY END USER |
    19. 6.16 UK MARKET ANALYSIS BY TYPE |
    20. 6.17 UK MARKET ANALYSIS BY CANCER TYPE |
    21. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    22. 6.19 UK MARKET ANALYSIS BY END USER |
    23. 6.20 FRANCE MARKET ANALYSIS BY TYPE |
    24. 6.21 FRANCE MARKET ANALYSIS BY CANCER TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    26. 6.23 FRANCE MARKET ANALYSIS BY END USER |
    27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE |
    28. 6.25 RUSSIA MARKET ANALYSIS BY CANCER TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    30. 6.27 RUSSIA MARKET ANALYSIS BY END USER |
    31. 6.28 ITALY MARKET ANALYSIS BY TYPE |
    32. 6.29 ITALY MARKET ANALYSIS BY CANCER TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    34. 6.31 ITALY MARKET ANALYSIS BY END USER |
    35. 6.32 SPAIN MARKET ANALYSIS BY TYPE |
    36. 6.33 SPAIN MARKET ANALYSIS BY CANCER TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    38. 6.35 SPAIN MARKET ANALYSIS BY END USER |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY TYPE |
    45. 6.42 CHINA MARKET ANALYSIS BY CANCER TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    47. 6.44 CHINA MARKET ANALYSIS BY END USER |
    48. 6.45 INDIA MARKET ANALYSIS BY TYPE |
    49. 6.46 INDIA MARKET ANALYSIS BY CANCER TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    51. 6.48 INDIA MARKET ANALYSIS BY END USER |
    52. 6.49 JAPAN MARKET ANALYSIS BY TYPE |
    53. 6.50 JAPAN MARKET ANALYSIS BY CANCER TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    55. 6.52 JAPAN MARKET ANALYSIS BY END USER |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY CANCER TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY END USER |
    64. 6.61 THAILAND MARKET ANALYSIS BY TYPE |
    65. 6.62 THAILAND MARKET ANALYSIS BY CANCER TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    67. 6.64 THAILAND MARKET ANALYSIS BY END USER |
    68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE |
    69. 6.66 INDONESIA MARKET ANALYSIS BY CANCER TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    71. 6.68 INDONESIA MARKET ANALYSIS BY END USER |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY CANCER TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY END USER |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE |
    78. 6.75 BRAZIL MARKET ANALYSIS BY CANCER TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    80. 6.77 BRAZIL MARKET ANALYSIS BY END USER |
    81. 6.78 MEXICO MARKET ANALYSIS BY TYPE |
    82. 6.79 MEXICO MARKET ANALYSIS BY CANCER TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    84. 6.81 MEXICO MARKET ANALYSIS BY END USER |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY CANCER TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY END USER |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY CANCER TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY END USER |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY END USER, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY END USER, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY END USER, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY END USER, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY END USER, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY END USER, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY END USER, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY END USER, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY END USER, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY END USER, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY END USER, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY END USER, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY END USER, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY END USER, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY END USER, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY END USER, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY END USER, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY END USER, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY END USER, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY END USER, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY END USER, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY END USER, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY END USER, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY END USER, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY END USER, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY END USER, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY END USER, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY END USER, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY CANCER TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY END USER, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Cancer Biologic Therapy Market Segmentation

Cancer Biologic Therapy Market By Type (USD Billion, 2025-2035)

  • Monoclonal Antibodies
  • Vaccines
  • Cytokines
  • Gene Therapy

Cancer Biologic Therapy Market By Cancer Type (USD Billion, 2025-2035)

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer

Cancer Biologic Therapy Market By Administration Route (USD Billion, 2025-2035)

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

Cancer Biologic Therapy Market By End User (USD Billion, 2025-2035)

  • Hospitals
  • Cancer Research Institutes
  • Cancer Biologic Therapy Market Companies
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.